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AhallmarkofParkinson’sdisease (PD) is the preferen-
tial loss of substantia nigra dopamine neurons. Here,
we identify a new parkin interacting substrate, PARIS
(ZNF746), whose levels are regulated by the ubiquitin
proteasome system via binding to and ubiquitination
by the E3 ubiquitin ligase, parkin. PARIS is a KRAB
and zinc finger protein that accumulates in models
of parkin inactivation and in human PD brain. PARIS
represses the expression of the transcriptional
coactivator, PGC-1a and the PGC-1a target gene,
NRF-1 by binding to insulin response sequences
in the PGC-1a promoter. Conditional knockout of
parkin in adult animals leads to progressive loss
of dopamine (DA) neurons in a PARIS-dependent
manner. Moreover, overexpression of PARIS leads
to the selective lossofDAneurons in the substantiani-
gra, and this is reversed by either parkin or PGC-1a
coexpression. The identification of PARIS provides
a molecular mechanism for neurodegeneration due
to parkin inactivation.INTRODUCTION
Parkinson’s disease (PD) is a progressive neurodegenerative
disorder that is characterized phenotypically by bradykinesia,
rigidity, tremor, and neuropsychiatric disturbances (Savitt
et al., 2006). Although the cause of PD in the majority of cases
is unknown, there are rare familial cases for which the genes
have been identified. There are at least sixteen PD associated
loci (Gasser, 2007). Mutations in a-synuclein and leucine rich
repeat kinase 2 (LRRK2) cause autosomal dominant PD. Four
genes have been linked to autosomal recessive PD (AR-PD)
and include mutations in parkin, DJ-1, PINK1, and ATP13A2.
Investigating the biology of these genes and their mutant proteinhas provided tremendous insight into the pathogenesis of both
familial and sporadic PD (Gasser, 2007; Savitt et al., 2006).
Parkin is an ubiquitin E3 ligase (Shimura et al., 2000; Zhang
et al., 2000). In general, PD-associated mutations in parkin lead
to loss of its E3 ligase function (Tanaka et al., 2004). Moreover,
oxidative, nitrosative, and dopaminergic stress, which play
important pathogenic roles in PD inactivate parkin, suggesting
that parkin inactivation may play a role in sporadic PD (Chung
et al., 2004; LaVoie et al., 2005; Winklhofer et al., 2003). Thus,
substrates of parkin that are subject to proteasomal degradation
should accumulate in animal and cellular models of parkin
inactivation and AR-PD due to parkin mutations, and also in
sporadic PD. There are a diverse array of parkin substrates
that has hindered the generation of a consensus in the field on
parkin’s physiologic function and pathologic role in PD. More-
over, parkin’s ability to mono- and polyubiquitinate as well as
ubiquitinate proteins with both lysine-48 and lysine-63 chains
hasmade it difficult to reconcile a common biochemical pathway
for parkin’s role in PD (Dawson and Dawson, 2010).
Here, we identify a new parkin interacting substrate, PARIS,
which provides a molecular mechanism for neurodegeneration
due to parkin inactivation in PD. Our results show that parkin
regulates the levels of PARIS via the ubiquitin proteasome
system (UPS). We show that PARIS is a major transcriptional
repressor of peroxisome proliferator-activated receptor gamma
(PPARg) coactivator-1a (PGC-1a) expression and that condi-
tional knockout (KO) of parkin in adult mice leads to progressive
loss of dopamine (DA) neurons through PARIS overexpression
and transcriptional repression of PGC-1a.
RESULTS
PARIS Is a KRAB and C2H2 Zinc Finger Protein
PARIS was identified by yeast two-hybrid screening using parkin
as bait (Zhang et al., 2000). Human PARIS (ZNF746) is a 644
amino acid protein that contains a Kruppel-associated box
(KRAB) at its N-terminus and a C2HC/C2H2 type zinc finger at
its C terminus (Figure 1A). There is a high degree of homologyCell 144, 689–702, March 4, 2011 ª2011 Elsevier Inc. 689
Figure 1. Identification of a Parkin Interacting Substrate, PARIS
(A) Schematic representation of PARIS. The conserved Kruppel associated Box (KRAB) and Zinc Finger motifs and their location are indicated.
(B) Regional analysis and levels of PARIS protein expression via immunoblot in various brain regions. Data = mean ± SEM, n = 3.
(C) Immunohistochemical distribution of PARIS in a sagittal and coronal sections of 6-week-old male C57BL mouse brain. Right upper panel shows an antigen
preabsorption control. Ctx, cerebral cortex; Hip, hippocampus; CPu, caudate putamen; SNpr, SN pars reticulata; SNpc, SN pars compacta; Th, thalamus; Cb,
cerebellum; (Cb); PC, Purkinje cells; ML, molecular cell layer; GL, granule cell layer; DG, dentate gyrus. Dashed (-) line outlines SN. High power view of SNpc
(rectangles in third row) is shown in the third row middle and right panels and lower middle and right panel. Scale bars represent 200 mm unless indicated, n = 3.
(D) Confocal microscopy demonstrates that endogenous PARIS and parkin are colocalizedmainly in the cytoplasm of rat cortical neurons. Top Panel, Parkin-red;
PARIS-green. Inset – high power view of an individual neuron. Bottom panel, Parkin-green; PARIS-red, Nucleus-DAPI-blue, merge-yellow, n = 4.
See also Figure S1.among human, mouse and rat PARIS proteins (Figure S1A).
Northern blot and immunoblot analysis reveals that PARIS is
expressed in all organs examined (Figures S1B and S1C). PARIS
is differentially expressed in the brain with low levels in cere-
bellum and midbrain (Figure 1B). Immunohistochemisty reveals
that PARIS is heterogeneously distributed throughout the brain
and that it is localized to neurons, including substantia nigra
(SN) pars compacta DA containing neurons (Figure 1C).
Confocal imaging indicates that PARIS is colocalized with parkin
in primary cortical neuron cultures (Figure 1D) and in SH-SY5Y
dopaminergic-like cells (Figure S1D).
Parkin Interacts with PARIS
MYC-tagged parkin and FLAG-tagged PARIS coimmunoprecipi-
tate in SH-SY5Y cells, whereas XIAP, a RING finger ubiquitin E3690 Cell 144, 689–702, March 4, 2011 ª2011 Elsevier Inc.ligase and ZNF398, a highly conserved homolog of PARIS do not
interact with PARIS and parkin, respectively (Figure 2A).
Recombinant GST-PARIS pulls down recombinant His-Parkin
indicating that PARIS and parkin directly interact (Figure 2B).
The familial PD-associated mutations in parkin, C431F,
R275W, and Q311X bind to PARIS less avidly than WT parkin,
whereas G430D mutant parkin binds to PARIS in a manner
similar to WT parkin (Figure 2C). PARIS coimmunoprecipitates
with parkin and parkin coimmunoprecipitates with PARIS from
whole human striatum (Figure 2D) or mouse brain (Figure S2A).
This endogenous interaction between parkin and PARIS is not
observed in parkin exon 7 KO brain (Figure 2E) confirming the
specificity of the interaction.
Domain mapping indicates that parkin binds to the C-terminal
domain, but not the N-terminal domain of PARIS (Figure S2B).
Figure 2. Parkin Interacts with PARIS
(A) Immunoprecipitated (IP) FLAG-PARIS interacts
with MYC-Parkin, but not MYC-XIAP or the PARIS
homolog, V5-ZNF398 (lane 6), n = 3.
(B) GST-pull down assay between parkin and
PARIS indicates a robust interaction between
parkin and PARIS, n = 4.
(C) Immunoprecipitated FLAG-PARIS interacts
with WT Parkin and Parkin mutants (C431F,
G430D, R275W, Q311X) in SH-SY5Y cells. Lower
panel, relative binding, data = mean ± SEM, n = 3,
*p < 0.05, Student’s t test.
(D) Immunoblot (IB) shows that Parkin and PARIS
coimmunoprecipitate in human striatum, n = 3.
(E) Parkin and PARIS coimmunoprecipitate from
WT mouse ventral midbrain, but not parkin KO
ventral midbrain, n = 3.
See also Figure S2.To ascertain which domain of parkin binds to PARIS, various
deletion constructs of MYC-tagged parkin were utilized. Coim-
munoprecipitation experiments show that both the RING1 or
RING2 domains are required for parkin binding to PARIS (Figures
S2C and S2D). Taken together these results indicate that parkin
interacts with the zinc finger domain of PARIS and PARIS binds
to either the RING1 or RING2 domain of parkin.
Parkin Ubiquitinates PARIS and Regulates PARIS Levels
FLAG-tagged PARIS is ubiquitinated by MYC-tagged parkin in
SH-SY5Y cells as shown by the substantial HA immunoreactivity
in the form of a smear, which is characteristic of polyubiquiti-
nated proteins (lane 3, Figure 3A). Familial linked parkin muta-
tions C431F, G430D, and Q311X have substantially reduced
ubiquitination activity against PARIS, whereas R275W has
modest activity (Figure 3A). The reduction in ubiquitination of
PARIS by these mutants is due, in part, to their reduced binding
(see Figure 2C) as well as reduced E3 ligase activity of these par-
kin mutants (Sriram et al., 2005).
FLAG-PARIS is ubiquitinated in the absence of exogenous
parkin (lane 2, Figures 3A and 3B). This endogenous ubiquitina-
tion is enhanced with coexpression of WT parkin (lane 3, FiguresCell 144, 689–73A and 3B). ShRNA-Parkin eliminates
the endogenous ubiquitination (lane 4,
Figure 3B). To control for potential off-tar-
gets effects of shRNA-parkin, a shRNA-
resistant WT parkin, but not a shRNA-
resistant Q311X parkin mutant restores
the ubiquitination of PARIS in the pres-
ence of shRNA-parkin (Figure 3B).
In vitro ubiquitin assays shows that
parkin ubiquitinates PARIS in the pres-
ence of various E2 enzymes including
UbcH5c (Figure S3A). There is no ubiqui-
tination signal in the absence of PARIS
(Figure S3B) and in the absence of parkin
(Figure S3C) indicating that the ubiquiti-
nation signal is specific for PARIS ubiqu-
tination. CHIP, which acts as a E4 forparkin (Imai et al., 2002), enhances the ubiquitination of PARIS
by parkin, but it has no affect in the absence of parkin indicating
that CHIP does not ubiquitinate PARIS directly (Figure S3D).
OTU1, a K48-linkage specific deubiquitinating enzyme (Messick
et al., 2008), successfully hydrolyzed the polyubiquitin chain on
PARIS (Figures S3E and S3F) and a K48-specific anti-ubiquitin
antibody, but not a K63 antibody detects the polyubiquitin chain
on PARIS (Figure S3E), suggesting that endogenous and exoge-
nous parkin ubiquitinates PARIS via K48 linkages.
The steady-state level of PARIS is regulated by the ubiquitin
proteasome system since the level of PARIS increases approxi-
mately two to three fold when SH-SY5Y cells are treated with the
proteasome inhibitor, MG132 (Figure 3C). The levels of PARIS
and parkin are tightly and significantly correlated (R2 = 0.9985)
in coexpression experiments in SH-SY5Y cells in which
increased levels of parkin lead to decreased levels of PARIS
(Figure 3D). Cyclohexamide (100 mg/ml) chase experiments in
SH-SY5Y cells transiently expressing GFP-tagged PARIS with
or without WT parkin or Q311X parkin demonstrate that the
decrease in the steady-state levels of PARIS is accelerated
in the presence of WT parkin compared with cells trans-
fected with GFP-vector or familial linked parkin Q311X mutant02, March 4, 2011 ª2011 Elsevier Inc. 691
Figure 3. Parkin Ubiquitinates and Regulates the Ubiquitin Proteasomal Degradation of PARIS
(A) WT MYC-Parkin ubiquitinates FLAG-PARIS (lane 3). Parkin mutants (C431F, G430D, Q311X) are unable to efficiently ubiquitinate FLAG-PARIS (lanes 4-7).
Ubiquitination (Ub(n)) is indicated on right with brackets, n = 3.
(B) Endogenous ubiquitination of PARIS (lane 2) is enhanced with exogenous WT Parkin (lane 3) and it is eliminated with shRNA-Parkin (lane 4). In the presence of
shRNA-Parkin, robust ubiquitination of PARIS is observed via coexpression of shRNA-resistant WT parkin (WTR) but not shRNA-resistant Q311X mutant parkin
(Q311XR), n = 3.
(C) 10 mM MG-132 increases PARIS steady-state levels compared to DMSO control. Bottom panel, relative PARIS levels normalized to b-actin, n = 3.
(D) Increasing ratio (1:1 to 4:1) of MYC-Parkin results in decreased steady-state levels of FLAG-PARIS (lanes 1-4). Bottom panel, relative PARIS and parkin levels
normalized to b-actin, n = 3; regression analysis, R2 = 0.9985, p < 0.05).
(E) WT Parkin decreases the steady-state levels of PARIS compared to mutant Q311X parkin or GFP transfected control cells in cyclohexamide (CHX)-chase
experiments in SH-SY5Y cells transiently expressing FLAG-PARIS. Bottom panel, relative PARIS levels normalized to b-actin, n = 3.
(F) MYC-parkin leads to degradation of FLAG-PARIS at a 4 to 1 ratio, respectively. 10 mM MG-132 prevents the degradation of FLAG-PARIS and MYC-Q311X
parkin has no effect, n = 3).
(G) PARIS accumulates after shRNA-Parkin and coexpression of shRNA resistant parkin (MYC-ParkinR) leads to robust degradation of PARIS, n = 3. Data =
mean ± SEM, *p < 0.05, **p < 0.01 and ***p < 0.001, ANOVA with Student-Newman-Keuls post hoc analysis (E, F, G) or Student’s t test (C).
See also Figure S3.(Figure 3E). Parkin at a 4 to 1 ratio with PARIS leads to a statisti-
cally significant reduction in PARIS that is blocked by MG132,
whereas the catalytically inactive Q311X parkin fails to reduce
PARIS levels (Figure 3F). ShRNA-Parkin leads to a significant
increase in the level of PARIS, which is reduced by expression
of a shRNA-resistant WT parkin (Figure 3G). These results taken692 Cell 144, 689–702, March 4, 2011 ª2011 Elsevier Inc.together suggest that parkin controls the levels of PARIS via the
ubiquitin proteasome system.
PARIS Accumulates in the Absence of Parkin Activity
PARIS levels are increased two fold in the cingulate cortex of AR-
PD patients, which lack functional parkin, versus age-matched
Figure 4. PARIS accumulates in AR-PD, sporadic PD and in animal models of parkin inactivation
(A) Immunoblot analysis of PARIS and b-actin in cingulate cortex from age-matched controls and AR-PD patient brains with parkin mutations.
(B) Quantitation of the immunoblots in panel A normalized to b-actin, n = 4.
(C) PARIS levels in cerebellum (CBM), frontal cortex (FC), striatum (STR) and SN of sporadic PD patient brains compared to age-matched controls.
(D) Relative PARIS levels normalized to b-actin in panel B, Controls n = 4; PD n = 5.
(E) Immunoblot analysis of PARIS in cortex (CTX), STR and ventral midbrain (VM) from WT and parkin exon 7 KO 18-24 month old mice.
(F) Relative protein levels of PARIS normalized to b-actin for panel E, WT n = 9; parkin KO n = 10.
(G) PARIS mRNA levels in indicated brain regions from WT and parkin exon 7 KO 18-24 month old mice.
(H) Top panel, experimental illustration of stereotaxic intranigral virus injection. Bottom panels, immunofluorescent images of TH (red), GFP (green) and merged
(yellow) in exon 7 floxed parkin mice (parkinFlx/Flx) after stereotactic delivery of Lenti-GFP or Lenti-GFPCre into the SNpc. 84.9 ± 1.9% and 78.1 ± 2.6% of TH
neurons express GFP and GFPCre, respectively, n = 3 per group. Enlarged images in the right bottom panels were taken from the white rectangle region from the
merged images of Lenti-GFPCre and Lenti-GFP, bar = 100 mm.
(I) Immunoblot analysis of parkin, PARIS, actin and GFP 4 weeks after intranigral Lenti-GFPCre or Lenti-GFP injection into parkinFlx/Flx mice.
(J) Relative protein levels of PARIS normalized to b-actin for panel I. Data =mean ±SEM, *p < 0.05, **p < 0.01 and ***p < 0.001, unpaired two-tailed Student’s t test
(B, J) and ANOVA test with Student-Newman-Keuls post hoc analysis (D, F, G).
See also Table S1 and Table S2.controls (Figures 4A and 4B). Due to the lack of tissue availability,
we were not able to assess the levels of PARIS in other brain
regions of AR-PD patients. PARIS levels are also increased by
more than two fold in both the striatum and the SN of sporadic
PD compared to controls (Figures 4C and 4D). We find no
alteration in the levels of PARIS mRNA in PD striatum or PD
SN versus control striatum and SN indicating thatthe increased level of PARIS is not due to a transcriptional
effect (see Figure 6A and Figure S5A). PARIS levels are not
increased in regions of the brain that are relatively unaffected
in PD including the cerebellum and the frontal cortex of sporadic
PD patients compared to controls (Figures 4C and 4D) sug-
gesting that the upregulation is primarily within the nigrostriatal
pathway.Cell 144, 689–702, March 4, 2011 ª2011 Elsevier Inc. 693
We next evaluated whether PARIS is increased in germline
parkin exon 7 KO mice (Von Coelln et al., 2004). PARIS is
modestly upregulated by approximately 48% in the striatum
and by 63% in ventral midbrain of germline parkin exon 7 KO
mice compared to age matchedWT controls, whereas the levels
of PARIS in the cortex is not changed (Figures 4E and 4F). The
upregulation of PARIS is not due to a transcriptional effect since
we find no difference in the level of PARISmRNA in germline par-
kin KO ventral midbrain and striatum versus WT ventral midbrain
and striatum(Figure 4G).
Since germline parkin exon 7 KO mice lack parkin from the
point of conception, it is possible that compensatory mecha-
nisms account for the lack of a more substantial upregulation
of PARIS (for review see (Dawson et al., 2010)). To avoid potential
developmental compensation, exon 7 was deleted in 6-8 week
old conditional parkin KO mice in which exon 7 was flanked by
loxP sites (parkinFlx/Flx) by SN stereotactic injection of a
GFP-fused Cre recombinase lentivirus (Lenti-GFPCre) and
compared to control SN injections of lentivirus expressing GFP
(Lenti-GFP) in parkinFlx/Flx mice (Figures 4H and 4I). Four weeks
after injection of the lentiviruses, Lenti-GFP and Lenti-GFPCre
effectively transduce neurons in the SN including DA neurons
(Figure 4H). Lenti-GFPCre leads to almost a complete loss of
parkin from the ventral midbrain of parkinFlx/Flx mice compared
to Lenti-GFP mice (Figures 4I and 4J). Accompanying the loss
of parkin is greater than a two-fold upregulation of PARIS. The
upregulation of PARIS in the conditional parkin exon 7 KOmodel
is not due to a transcriptional effect since there is no alteration in
PARIS mRNA in the conditional parkin KO ventral midbrain
versus WT ventral midbrain (Figure S5E). Thus, the levels of
PARIS are increased in conjunction with parkin inactivation
and impairment of ubiquitin-mediated proteasomal degradation
in sporadic PD, AR-PD and in an animal model of parkin
inactivation.
PARIS Is a Transcriptional Repressor of PGC-1a
Proteins with KRAB domains can function as transcriptional
repressors (Witzgall et al., 1994). GAL4-BD fused PARIS leads
to decreased luciferase activity from a 5 X GAL4-luciferase
reporter construct, which is restored by coexpression of WT
parkin, but not Q311X mutant parkin (Figure S4A). To identify
the PARIS DNA-binding consensus sequence, a chimeric
protein containing the zinc finger domain (ZF) of PARIS (amino
acids, 453–589) fused in frame to glutathione-S-tranferase
(GST), GST-ZF-PARIS, was used in a cyclic amplification and
selection of targets (CAST) assay (Figure 5A) (Funk and Wright,
1992; Shields and Yang, 1998). Immobilized GST-ZF-PARIS
was incubated with a pool of oligonucleotides containing 26
random nucleotides. The final pool of oligonucleotides remaining
after four rounds of CASTing followed by three rounds of electro-
phoretic mobility shift assays (EMSA) were cloned, sequenced
and analyzed. Alignment of all the sequences using the program
MACAW (National Center for Biotechnology Information) reveals
a consensus sequence with a core sequence composed of
TATTTT (T/G) (Figure 5A). Nineteen out of twenty-four sequences
contained the core sequence and 3 out of 19 sequence tags
were identified as duplicates indicating this is the primary
DNA-binding sequence for PARIS. The TATTTT (T/G) consensus694 Cell 144, 689–702, March 4, 2011 ª2011 Elsevier Inc.sequence is an insulin response sequence (IRS) designated the
phosphoenolpyruvate carboxykinase (PEPCK)-like motif (PLM)
(Daitoku et al., 2003; O’Brien et al., 2001), which is involved in
the regulation of transcripts involved in energy metabolism and
insulin responsiveness (Mounier and Posner, 2006).
A NCBI survey of IRS/PLM responsive transcripts reveals that
members of the PPARg coactivator-1 (PGC-1) family of tran-
scriptional coactivators are regulated by IRS sites. PGC-1a
contains three IRS/PLM elements within its 50-promoter region
(Figure 5B). The activity of the 1kb human PGC-1a promoter is
decreased approximately 40% in the presence of PARIS, which
is rescued by parkin overexpression (Figure 5B). Similar
results are observedwith the 2 KbmousePGC-1a promoter (Fig-
ure S4B). The familial parkin mutant, Q311X, has minimal effects
on the PGC-1a promoter (Figure 5B). PARIS represses PGC-1a
promoter activity by binding to the IRS sites, since it fails to
inhibit the reporter in which the three IRS sites are deleted in
the context of the PGC-1a promoter-reporter construct
(Figure 5B).
Individual IRS site mutants (IRS1-M, IRS2-M, IRS3-M) within
the PGC-1a reporter that disrupt PARIS binding to the PGC-1a
promoter as determined by EMSA (see Figure 5C) and
a promoter construct, IRS123-M, containing all three mutations
were evaluated in the promoter reporter assay (Figure S4C).
IRS1-M and IRS3-M substantially reduce PGC-1a reporter
promoter activity, whereas IRS2-M increases the activity (Fig-
ure S4C). PARIS overexpression inhibits IRS1-M, IRS2-M,
IRS3-M PGC-1a reporter promoter activity suggesting that
PARIS binds to and regulates all three sites (Figure S4C) as indi-
cated from the EMSA assays (Figure 5C).
EMSA shows that PARIS binds to the PGC-1a IRS elements
since GST-PARIS (full length) elicits a shift of [32P]-labeled
oligonucleotides containing the IRS1, IRS2, and IRS3 sequences
of the PGC-1a promoter, whereas it fails to cause a shift of IRS1,
IRS2 and IRS3 containing a single base substitution within the
IRS sequence (Figure 5C). Additionally eight zinc finger mutants
of PARIS were assessed for their ability to repress the PGC-1a
reporter promoter construct (Figure S4D and S4E). M1, M2,
M8 PARIS mutants are able to repress PGC-1a reporter
promoter activity, similar to WT PARIS. M3, M4, M5, M6 PARIS
mutants partially repress PGC-1a reporter promoter activity,
whereas the M7 (C571A) PARIS mutant has no affect on
PGC-1a reporter promoter activity. The M7 GST-C571A-PARIS
mutant has substantially reduced IRS-binding capacity as deter-
mined by EMSA (Figure S4F).
Chromatin immunoprecipitation (ChIP) indicates that PARIS
binds to the endogenous PGC-1a promoter in SH-SY5Y cells
(Figure 5D) and mouse brain (Figure 5E). PARIS also binds to
the endogenous PGC-1a promoter in human brain (Figure 5F)
and consistent with its upregulation in PD striatum (see Fig-
ures 4C and 4D) there is enhanced PARIS occupancy of endog-
enous PGC-1a in PD striatum compared to control (Figure 5G).
We performed luciferase reporter assay in SH-SY5Y cells and
ChIP assays in PD versus control striatum and SH-SY5Y cells
with phosphoenolpyruvate carboxykinase (PEPCK) (Figure S4G)
and glucose-6-phosphatase (G6Pase) (Figure S4H). The lucif-
erase reporter assay shows that overexpression of PARIS
enhances the promoter activity of rat PEPCK, but not mouse
Figure 5. PARIS Acts as Transcriptional Repressor of PGC-1 a
(A) Identification and MACAW alignment of the PARIS DNA-binding sequence as determined by CASTing. Darker colors represent a greater degree of overlap of
the segment pairs (bottom right - % overlap). Asterisk, duplicate sequence tags.
(B) Relative luciferase activity of the 1-kilobase human PGC-1a (992 to +90) compared to Renilla luciferase ± PARIS or ± parkin or ± familial mutant Q311X
parkin, n = 3. Location of IRS, CREmotifs and oligos for human ChIP (arrows) in the PGC-1a promoter construct (top of panel). Immunoblot analysis confirms the
expression of FLAG-PARIS, MYC-Parkin and MYC-Q311X parkin (right panel).
(C) EMSA ofGST-PARIS of 32P-labeledWT (WT-32P) IRS oligonucleotides (IRS1-WT, IRS2-WT, IRS3-WT) of the humanPGC-1a promoter and 32P-labeledmutant
(T/g) (MT-32P) IRS oligonucleotides (IRS1-MT, IRS2-MT, IRS3-MT). Unlabeled WT (WT cold) IRS oligonucleotides disrupt the GST-PARIS-DNA protein
complexes with the WT-32P IRS oligonucleotides, n = 3. Unlabeled mutant probes (MT cold) has no effect on mutant (MT-32P). Arrow indicates specific PARIS-
shifted probe; NS, nonspecific; FS, fragmented PARIS-shifted probe; FP, free probe.
(D) PARIS occupies the endogenous PGC-1 a promoter as determined by ChIP assay with anti-PARIS polyclonal antibodies in SH-SY5Y cells, n = 3.
(E) PARIS occupies the endogenous mouse PGC-1 a promoter as determined by ChIP in mouse whole brain, n = 3. Mouse specific IRS primers are indicated in
Figure S4B.
(F) ChIP assay of endogenous PARIS binding to the IRS region of the human PGC-1a promoter in human PD and aged-matched control (CTL) striatum, control
n = 3; PD n = 4.
(G) Quantitation of ChIP in panel F. Human specific IRS primers for D and F are indicated in panel B.
(H) Real-time qRT-PCR of PGC-1a, GFP and b-actin following transient transfection of GFP, GFP-PARIS or GFP-C571A PARIS mutant, n = 4.
(I) Immunoblot analysis of PGC-1a, GFP and b-actin following transient transfection of GFP, GFP-PARIS or GFP-C571A PARIS mutant, n = 4.
(J) Quantitation of the immunoblots in panel I normalized to b-actin, n = 4.
(K) Immunoblot analysis of parkin, PARIS, PGC-1a and b-actin in double-knockdown experiments via lentiviral transduction of shRNA-parkin and/or shRNA-
PARIS in SH-SY5Y cells, n = 3.
(L) Quantitation of the immunoblots in panel K normalized to b-actin, n = 3, sh = shRNA.
(M) Relative mRNA levels of PGC-1a normalized to GAPDH, n = 3. Quantitative data = mean ± SEM, *p < 0.05, **p < 0.01, ***p < 0.001, unpaired two-tailed
Student’s t test (G), ANOVA with Student-Newman-Keuls post hoc analysis (B, H, J, L, M).
See also Figure S4 and Table S2, Table S3, and Table S5.
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G6Pase promoter activity (Figure S4I). The ChIP assay demon-
strates that PARIS binds to the endogenous promoter of human
PEPCK and G6Pase in SH-SY5Y cells and in control and PD
postmortem striatum (Figure S5J). In contrast to PGC-1a, there
is not enhanced occupancy of the PEPCK andG6Pase promoter
by PARIS. These data suggest that PARIS can bind to the
promoter of PEPCK and G6Pase, but in contrast to PGC-1a it
positively regulates PEPCK and it has no appreciable effect on
G6Pase. Thus, the transcriptional repressive effects of PARIS
are relatively specific to PGC-1a.
GFP-WT-PARIS overexpression leads to approximately
a 75% reduction in PGC-1a mRNA (Figure 5H) and approxi-
mately a 60% reduction in protein levels of PGC-1a (Figures 5I
and 5J), whereas the GFP-C571A-PARIS mutant has no effect
on PGC1-a protein or message levels (Figures 5H–5J). Lentiviral
shRNA-parkin leads to a two fold increase in the level of PARIS
followed by a 66% reduction of PGC-1a (Figures 5K and 5L).
To determine whether the reduction in PGC-1a levels induced
by the absence of parkin is dependent on the presence of PARIS,
a double-knockdown experiment was performed by lentiviral
shRNA-parkin and/or shRNA-PARIS in SH-SY5Y cells. Knock-
down of PARIS prevents the downregulation of PGC-1a levels
induced by parkin knockdown (Figures 5K and 5L). Knockdown
of PARIS results in a 3 fold increase in PGC-1a protein levels
(Figures 5K and 5L) and a 3.5 fold increase in PGC-1a mRNA
(Figure 5M). Knockdown of PARIS in the setting of parkin knock-
down also prevents the downregulation of PGC-1a mRNA
(Figure 5M). These results taken together indicate that PARIS
is a transcriptional repressor that negatively regulates the levels
of endogenous PGC-1a and that the downregulation of PGC-1a
in the absence of parkin is due to the upregulation of PARIS.
Identification of NRF-1 as a Potential In Vivo PGC-1a
Target Gene in PD
PGC-1a is a transcriptional coactivator that regulates a variety of
genes (Lin et al., 2005; St-Pierre et al., 2006). To determine which
PGC-1a target genes are coregulated by PARIS in PD, real-time
quantitative RT-PCR (qRT-PCR) was performed on a variety of
PGC-1a target genes in PD SN and striatum. We measured the
levels PGC-1a coregulated genes that play important roles in
mitochondrial function and oxidant metabolism including
nuclear respiratory factor-1 (NRF-1), copper/zinc superoxide
dismutase (SOD1), manganese SOD (SOD2), glutathione perox-
idase (GPx1), catalase (CAT), mitochondrial uncoupling proteins
(UCP2 and UCP3), mitochondrial transcription factor A (Tfam)
and the oxidative phosphorylation regulators, ATP5b, cyto-
chrome C (CytC) and cytochrome C oxidase (COX II and IV)
(Figure 6A and Figure S5A). In addition, the levels of other genes
containing IRS/PLM in their promoter including PEPCK, G6Pase,
insulin-like-growth-factor-binding protein 1 (IGFBP-1), tyrosine
aminotransferase (TAT), and apolipoprotein C III (APOC3) were
monitored along with PGC-1a to assess whether PGC-1a is
selectively affected in PD (Figure 6A and Figure S5A). The levels
of PARIS and parkin were also assessed as controls.We find that
PGC-1a and NRF-1 mRNA are downregulated in PD SN and
striatum compared to control SN and striatum (Figure 6A and
Figure S5A). In PD SN ATP5B is also significantly downregulated
and CAT is significantly upregulated (Figure 6A). All other696 Cell 144, 689–702, March 4, 2011 ª2011 Elsevier Inc.PGC-1a dependent genes are not significantly altered (Figure 6A
and Figure S5A). In addition there is no significant change in the
levels of the IRS/PLM responsive transcripts PEPCK, G6Pase
and IGFBP-1 (Figure 6A and Figure S5A). TAT and APOC3 are
not detectable. No significant alteration in the mRNA level of
PARIS and parkin is observed between PD and control SN and
striatum (Figure 6A and Figure S5A) indicating that the upregula-
tion in PARIS protein levels (see Figures 4C and 4D) are most
likely due to impairment of parkin E3 ubiquitin ligase activity.
Moreover, the absence of an alteration in the mRNA levels of
PARIS and parkin suggest that the changes in the mRNA levels
of PGC-1a and NRF-1 are specific and not due to the degener-
ative process that occurs in PD.
As shown above (see Figures 4C and 4D) PARIS protein is
upregulated almost 3-fold in PD SN (Figures 6B and 6C) and
greater than two-fold in PD striatum (Figure S5B and S5C)
compared to control SN and striatum respectively. Accompa-
nying the upregulation of PARIS is the downregulation of PGC-
1a and NRF-1 in SN (Figures 6B and 6C) and striatum (Figures
S5B and S5C). There is a trend toward redistribution of parkin
from the soluble to insoluble fraction in SN (Figures 6B and 6C)
and parkin shifts from the soluble to insoluble fraction in PD
striatum (Figures S5B and S5C). There is a strong negative
correlation between the protein levels of PARIS and PGC-1a
(R2 = 0.5195, p < 0.05) and NRF-1 (R2 = 0.8015, p < 0.01) in
the striatum and between PARIS and PGC-1a (R2 = 0.6955,
p < 0.05) and NRF-1 (R2 = 0.5979, p < 0.05) in the SN and
a positive correlation between PGC-1a and NRF-1 striatum
(R2 = 0.6827, p < 0.05) and SN (R2 = 0.6488, p < 0.05)
(Figure S5D). These results taken together indicate that PARIS
accumulates in the nigrostriatal pathway in PD leading to the
downregulation of PGC-1a and the PGC-1a dependent gene,
NRF-1.
Downregulation of PGC-1a and NRF-1 in Conditional
Parkin KO Mice Requires PARIS
In adult conditional parkin KO mice (see Figures 4H–4J) four
weeks after Lenti-GFPCre mediated parkin deletion there is
a greater than two fold upregulation of PARIS (Figures 6D and
6E and Figures 4H–4J), comparable to that which occurs in
sporadic PD SN (see Figures 4C and 4D) and a concomitant
downregulation of PGC-1a and NRF-1 (Figures 6D and 6E).
The alteration of PGC-1a and NRF1 results from the reduction
of their mRNA levels (Figure 6F). Moreover, we analyzed the
mRNA levels of PGC-1a target genes in the ventral midbrain of
the Lenti-GFPCre-mediated conditional parkin KO and show
a significant reduction of PGC-1a, SOD2, and NRF-1 and no
significant alteration in other sampled PGC-1a regulated tran-
scripts (Figure S5E) similar to what occurs in sporadic PD brain.
In addition, the levels of other genes containing IRS/PLM in their
promoter including PEPCK, G6Pase, IGFBP-1, TAT, and APOC
were monitored. Of the genes containing IRS/PLM in their
promoters, only PGC-1a is significantly downregulated
(Figure S5E). The upregulation of PARIS and subsequent down-
regulation of PGC-1a and NRF-1 occurs prior to the loss of DA
neurons since there is no appreciable loss of DA neurons at
3 months after the Lenti-GFPCre injection (see Figure 6H). More-
over, laser capture microdissection (LCM) was performed prior
Figure 6. Identification of PGC-1a and NRF-1 as Pathological In Vivo Targets of Accumulated PARIS in PD Brain and Conditional
Parkin KO Mice
(A) Real-time qRT-PCR of IRS (PEPCK-like motif)-containing genes and PGC-1a dependent genes in PD SN compared to age-matched CTL-SN normalized to
GAPDH, n = 3–4 per group.
(B) Immunoblots of PARIS, PGC-1a, parkin and NRF-1 in soluble and insoluble fractions of PD SN compared to age-matched CTL-SN.
(C) Quantitation of the immunoblots in panel B normalized to b-actin, PD, n = 4; Control, n = 3.
(D) Top panel, experimental illustration of stereotaxic intranigral virus injection. Below are immunoblots of parkin, PARIS, PGC-1a, NRF-1, b-actin and GFP,
4 weeks after stereotactic delivery of Lenti-GFP, Lenti-GFPCre, Lenti-GFPCre + shRNA-dsRed, or Lenti-GFPCre + shRNA-PARIS into exon 7 floxed parkin mice
(parkinFlx/Flx), n = 3 per group. *nonspecific band.
(E) Quantitation of the immunoblots in panel D normalized to b-actin, n = 3 per group.
(F) The alteration of PGC-1a and NRF1 shown in panel D and E results from transcriptional changes as determined by real-time qRT-PCR, n = 3 per group.
(G) Top panel, experimental illustration of stereotaxic intranigral virus injection. Below is TH immunostaining of representative mice midbrain sections from SN of
parkinFlx/Flx mice injected with Lenti-GFP, and Lenti-GFPCre ± Lenti-shRNA-PARIS 10 months post-injection of virus.
(H) Stereological assessment of TH and Nissl positive neurons in the SN of parkinFlx/Flx mice injected with Lenti-GFP, and Lenti-GFPCre ± Lenti-shRNA-PARIS 3
(n = 3 per group) and 10 months (n = 7 per group) after injection of virus. Data =mean ± SEM, *p < 0.05, **p < 0.01 and ***p < 0.001, unpaired two-tailed Student’s
t test (A and C) and ANOVA with Student-Newman-Keuls post hoc analysis (E,F, and H).
See also Figure S5, Table S4, and Table S5.
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to the loss of DA neurons to obtain mRNA from TH positive
neurons transduced with GFP-Cre from conditional parkin KO
mice 4 weeks after the Lenti-GFPCre injection to ascertain
whether the reduction of PGC-1a is cell autonomous in DA
neurons (Figures S5F and S5G). We find a robust reduction of
PGC-1a mRNA in TH-positive DA neurons of conditional parkin
KO mice, whereas the levels of PARIS mRNA are unchanged
(Figure S5F and S5G). PARIS is only modestly upregulated in
germline parkin exon 7 KO mice (also see Figures 4E and 4F).
PGC-1a and NRF-1 protein levels in germline parkin exon 7 KO
mice are comparable to those of WT mice (Figures S5H and
S5I). Thus, germline deletion of parkin apparently leads to
compensatory changes that prevent substantial alterations in
the levels of PGC-1a and NRF-1.
We further developed the Cre-flox conditional parkin exon
7 KO model by introducing lentiviral shRNA-PARIS along with
lenti-GFPCre into parkinFlx/Flx mice to address whether the
changes in PGC-1a and NRF-1 are due to PARIS (Figures
6D–6F). Coadministration of lentiviral shRNA-PARIS along with
Lenti-GFPCre prevents the changes in PGC-1a and NRF-1
protein and mRNA as compared to control lentiviral
shRNA-dsRed plus Lenti-GFPCre (Figures 6D–6F). These results
taken together indicate that PARIS accumulates in the nigrostria-
tal pathway in PD and in models of parkin inactivation leading to
the downregulation of PGC-1a and the PGC-1a dependent
gene, NRF-1. These changes in PGC-1a and NRF-1 due to the
loss of parkin are cell autonomous and precede the loss of DA
neurons and are due to the upregulation of PARIS, since knock-
down of PARIS prevents these changes. Moreover, since
deletion of parkin from adult mice leads to similar events that
occur in sporadic PD, it is likely that the absence and/or inactiva-
tion of parkin in PD leads to PARIS upregulation and impairment
of PGC-1a signaling.
Neurodegeneration in Conditional Parkin KO Mice
Requires PARIS
Conditional KO of parkin leads to a significant reduction in tyro-
sine hydroxylase (TH) positive and Nissl stained DA neurons
10 months after stereotaxic injection of Lenti-GPFCre into the
SN of 6- to 8-week-old parkinFlx/Flx mice compared to
parkinFlx/Flx mice injected with control Lenti-GFP (Figures 6G
and 6H). The loss of DA neurons is progressive, since there is
no substantial loss of DA neurons after 3 months (Figure 6H).
PARIS is required for the loss of DA neurons in conditional parkin
KO mice, since coadministration of lentiviral shRNA-PARIS
along with Lenti-GFPCre significantly reduces the loss of DA
neurons due to conditional KO of parkin (Figures 6G and 6H).
Taken together these results indicate that conditional KO of
parkin in adult mice leads to degeneration of DA neurons and
the upregulation of PARIS is necessary to contribute to the
demise of DA neurons.
Overexpression of PARIS Kills Dopamine Neurons
In Vivo: Restoration by Parkin and PGC-1a
A PARIS overexpression model was developed in which
AAV1-PARIS was stereotactically injected into the SN of
C57Bl/6 mice and compared to mice injected with control
AAV1-GFP virus (Figure 7). Stereotactic intranigral injection of698 Cell 144, 689–702, March 4, 2011 ª2011 Elsevier Inc.AAV1 effectively transduces the entire SN (Figure 7A). One
month after stereotactic injection of the viruses, AAV1 mediated
overexpression of PARIS leads to a greater than two-fold
upregulation of PARIS levels in the SN of mice (Figures 7B and
7C) and it has no affect on parkin levels (Figures 7B and 7C).
Accompanying the increase in PARIS levels is a concomitant
downregulation of PGC-1a and NRF-1 protein levels (Figures
7B and 7C).
PARIS overexpression leads to a greater than 40% reduction
in TH positive and Nissl stained DA neurons positive neurons
(Figure 7D and Figure 7E). We do not observe any substantial
decrement in GABAergic neurons as assessed by GAD65/67
immunoreactivity via immunohistochemistry (Figure S6A) or via
immunoblot (Figures S6B and S6C) in AAV1-PARIS versus
AAV1-GFP transduced SN, indicating that PARIS overexpres-
sion is selectively detrimental to DA neurons. Coadministration
of AAV1-Parkin with AAV1-PARIS prevents the loss of dopamine
neurons induced by PARIS overexpression (Figures 7D and 7E).
Lentiviral PGC-1a also prevents the loss of DA neurons induced
by PARIS overexpression (Figures 7D and 7E). AAV1-mediated
overexpression of PARIS was confirmed by immunoblot analysis
and reduces PGC-1a and NRF-1 levels by 52% and 60%,
respectively. These reductions are restored by co-overexpres-
sion of parkin or PGC-1a (Figures7F and 7G). These results indi-
cate that PARIS overexpression is sufficient to downregulate
PGC-1a, NRF-1 and selectively kill DA kills neurons through
a PGC-1a dependent mechanism.
DISCUSSION
PARIS (ZNF746) Is a Parkin Substrate
PARIS fulfills several criteria for a parkin substrate and in the
absence of parkin activity in PD it accumulates making it an
attractive pathogenic substrate. In sporadic PD, PARIS only
accumulates in the striatum and SN. The selective inactivation
of parkin in the striatum and SN in sporadic PD through nitrosa-
tive and dopaminergic stress (Chung et al., 2004; LaVoie et al.,
2005) and c-Abl phosphorylation (Ko et al., 2010) most likely
accounts for the accumulation of PARIS. Similarly, in parkin
exon 7 KO mice, PARIS is only upregulated in the striatum and
SN. However, PARIS accumulates in the cingulate cortex of
AR-PD brains, suggesting that parkin can regulate the ex-
pression of PARIS outside the striatum and SN. Whether there
is a differential regional or temporal upregulation of PARIS in
AR-PD brains is not known as tissue from these areas was
unavailable for analysis. The lack of an upregulation in the cortex
of parkin exon 7 mice, suggests that there may differential and
selective regulatory mechanisms in the cortex versus the stria-
tum and SN.
PARIS Is a Transcriptional Repressor of PGC-1a
PARIS is a member of the family of KRAB zinc-finger proteins
(KRAB-ZFPs) transcriptional repressors (Looman et al., 2002).
Homologs of PARIS exist in simpler organisms suggesting that
PARIS function may be evolutionarily conserved. PARIS seems
to bind exclusively to IRS/PLM motifs, which provide an
important site of regulation of a variety of IRS/PLM responsive
proteins (Daitoku et al., 2003;Mounier and Posner, 2006; O’Brien
Figure 7. Introduction of AAV1-Parkin or Lenti-PGC-1a in Mice SN Protects from AAV1-PARIS-Mediated Selective Dopaminergic
Neuronal Toxicity
(A) Schematic illustration of intranigral viral injection and transduced brain regions.
(B) Immunoblot analysis of PARIS, PGC-1a, parkin and NRF-1 four-weeks post intranigral injection of AAV1-PARIS, n = 5 per group.
(C) Quantitation of the immunoblots in panel B normalized to b-actin.
(D) TH staining of a representative section of mice injected with AAV1-GFP, AAV1-PARIS ± AAV1-parkin or AAV1-PARIS ± Lenti-PGC-1a. Each panel shows the
noninjected side (Non) and contralateral injected side (Inj) and white pentagonal box indicates the SNpc. Enlarged images containing SNpc and SNpr are shown
on the right panels. AAV1 encoding GFP was used as transduction control in all injection procedures. Broad regions including SNpc and SNpr were successfully
transduced (left top panel). In right bottom panel, yellow rectangle indicates the region that PARIS and lenti- PGC-1a cotransduced. Approximately 30% of the
SNpc was transduced with lenti-PGC-1a and this is the region, which is protected from PARIS toxicity, n = 6 per group.
(E) Stereological TH, Nissl-positive neuronal counting, n = 6 per group.
(F) Immunoblot analysis of PARIS, PGC-1a, parkin and NRF-1, n = 3.
(G) Quantitation of the immunoblots in panel F normalized to b-actin.
(H) Parkin-PARIS-PGC-1a pathway as a model in PD. Endogenous PARIS acts to maintain the balance of PGC-1a levels. In PD, parkin is inactivated by diverse
insults such as familial mutations, reactive oxygen species (ROS), nitrosative (NO) and dopamine (DA) stress and PARIS accumulates. Accumulated PARIS
continuously inhibits PGC-1a transcription leading to reduction in PGC-1a dependent genes. Ultimately this situation results in neurodegeneration in PD. Data =
mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001; ANOVA with the Student-Newman-Keuls post hoc test.
See also Figure S6.et al., 2001). Our studies reveal that PGC-1a levels are potently
and selectively regulated by PARIS, consistent with the observa-
tion that PGC-1a transcription is controlled by IRS/PLM motifs
(Finck and Kelly, 2006). In PD SN and striatum and conditional
parkin KO midbrain, PGC-1a is the only IRS/PLM regulated
gene that is downregulated suggesting that PARIS selectively
represses PGC-1a expression in PD.
Notably PARIS is a physiological transcriptional repressor
of PGC-1a, which directly and endogenously occupies the
cis-regulatory elements of PGC-1a. PGC-1a is a transcriptional
coactivator that controls the transcription of many genes
involved in cellular metabolism including mitochondrial biogen-esis and respiration and ROS metabolism (Finck and Kelly,
2006; St-Pierre et al., 2006). The levels of PGC-1a dependent
genes are controlled in large part by the nature and composition
of the PGC-1a transcriptional coactivator complex (Finck and
Kelly, 2006). The PGC-1a dependent gene, NRF-1, appears to
be particularly susceptible to the inhibitory effects of PARIS.
It is likely that there is not only a PARIS transcriptional
repressor protein complex that plays important regulatory roles
in PARIS-mediated transcriptional repression and specificity
but the repression of PARIS relies on the genomic context rather
than simple IRS motif. In addition, under certain contexts it
appears as though PARIS can act a transcriptional activator.Cell 144, 689–702, March 4, 2011 ª2011 Elsevier Inc. 699
Consistent with this notion are our observations that PARIS can
bind the PEPCK or G6Pase endogenous promoters via ChIP and
it has no effect on G6Pase promoter-reporter activity, but
enhances PEPCK promoter-reporter activity. DNA response
elements can function as allosteric effectors that determine the
transcriptional activity of regulators, explaining that regulators
may activate transcription in the context of one gene, yet repress
transcription in another (Lefstin and Yamamoto, 1998). Indeed,
the IRS motifs in the PGC-1a promoter are organized differently
then the IRS motifs of the PEPCK and G6Pase promoters, which
may, in part account for the ability of PARIS to act as both
a repressor and an activator. Other IRS/PLM responsive genes
are likely to be regulated by PARIS and the identification of these
genes, their potential regulation by PARIS and their potential role
in PD requires additional study.
Dopaminergic Degeneration in Conditional Parkin
KO Mice
Germline deletion of parkin using a variety of approaches
created parkin KO mice with minimal phenotypes and no loss
of DA neurons (Goldberg et al., 2003; Von Coelln et al., 2004).
A number of reasons were recently put forward regarding the
lack of overt degeneration of DA neurons in genetic animal
models of PD including compensatory mechanisms (Dawson
et al., 2010). Similar compensatory mechanisms are likely to
occur in PD (Bezard et al., 2003; Palop et al., 2006), and com-
pensation accounts, in part, for the age-dependence of PD.
The ultimate failure of these compensatory mechanisms con-
tributes to neurodegeneration.
Since, our germline parkin exon 7 KO mice (Von Coelln et al.,
2004) do not have degeneration of DA neurons, we generated
conditional parkin exon 7 KOmice and deleted parkin from adult
mice to avoid developmental compensation. Similar to germline
deletion of parkin, embryonic deletion of glial-cell-line-derived
neurotrophic factor (GDNF) had no deleterious effects on DA
neurons (Pascual et al., 2008). However, conditional KO of
GDNF in adult animals using a tamoxifen sensitive Cre-Lox
recombination unmasked the ‘‘true physiologic action of
GDNF’’ and led to mice with profound degeneration of catechol-
aminergic neurons (Pascual et al., 2008), indicating that develop-
mental compensation can be overcome by deleting genes in the
DA system in adulthood (for review see (Dawson et al., 2010)).
Similar to the adult GDNF deleted mice, we observed pro-
gressive loss of DA neurons when parkin is deleted in adult
mice. PARIS levels increase in parkin conditional KOmice similar
to levels in AR-PD brain and in sporadic PD SN. Accompanying
the upregulation of PARIS is downregulation of PGC-1a and NRF
in conditional KO mice similar to the downregulation in sporadic
PD striatum and SN. Consistent with the notion that compensa-
tion occurs in the germline parkin KOmice is the observation that
PARIS is only modestly elevated and there is no alteration in the
levels of PGC-1a and NRF and there is no loss of DA neurons.
Parkin, PARIS, PGC-1a, and Neurodegeneration
We cannot be certain that PARIS is the sole substrate or mech-
anism that contributes to DA neuron degeneration following
parkin inactivation. Recent studies suggest that PINK1 in
a mitochondrial membrane potential-dependent manner signals700 Cell 144, 689–702, March 4, 2011 ª2011 Elsevier Inc.and recruits parkin through as of yet unclear mechanisms from
the cytoplasm to the mitochondria to initiate degradation of
damaged mitochondria through autophagy (mitophagy) (Vives-
Bauza and Przedborski, 2010). Since PGC-1a and NRF-1 are
major transcriptional regulators of mitochondrial biogenesis
(Finck and Kelly, 2006; St-Pierre et al., 2006; Ventura-Clapier
et al., 2008; Wu et al., 1999), it is conceivable that when parkin
decreases the number of mitochondria through mitophagy in
response to mitochondrial damage, it is counter balanced by
downregulation of PARIS levels as a homeostatic mechanism
to increase mitochondrial size and number through regulation
of PGC-1a and NRF-1 levels. The contribution of other parkin
substrates that are regulated by the UPS and accumulate in
AR-PD, sporadic PD and models of parkin inactivation, such
as the aminoacyl-tRNA synthetase interacting multifunctional
protein type 2 (AIMP2) also known as p38/JTV-1 (Corti et al.,
2003; Ko et al., 2005) and far upstream element-binding protein
1 (FBP-1) (Ko et al., 2006), as well as others are not known.
Additional substrates and mechanisms will need to be evaluated
in future studies to determine their relative contributions to DA
neuron degeneration due to parkin inactivation. However, we
can be confident that PARIS upregulation is necessary and
sufficient to cause DA neuron degeneration in models of parkin
inactivation and that maintaining PGC-1a function is beneficial.
Indeed PGC-1a has been implicated in other models of PD
(St-Pierre et al., 2006). Moreover, PGC-1a-responsive genes
are underexpressed in microdissected dopaminergic neurons
of PD suggesting that the alteration of PGC-1amight be a cause
of PD pathogenesis, not the consequence (Zheng et al., 2010).
Herein, we hypothesize a model that accumulated PARIS in
the setting of parkin’s inactivation represses PGC-1a expression
leading to neurodegeneration. Consistent with this hypothesis
are the observations that the reduction in PGC-1a levels and
neurodegeneration are substantially reduced by knocking
down PARIS levels in the setting of parkin inactivation. Since
PARIS is likely to regulate other genes, the Parkin-PARIS-
PGC-1a pathway is one potential contributory mechanism to
PD pathogenesis. This parkin-PARIS-PGC-1a neurodegenera-
tive pathway ultimately results in the selective vulnerability of
dopamine neurons and accounts, in part, for the neurodegener-
ation in PD (Figure 7H). Further study is required to determine the
full implications of the parkin-PARIS-PGC-1a neurodegenerative
pathway in PD. Nonetheless, our results suggest that parkin
inactivation acting through PARIS and downregulation of
PGC-1a contributes to the pathogenesis of PD.EXPERIMENTAL PROCEDURES
Yeast Two-Hybrid Screening
Saccharomyces cerevisiaeMaV203 was transformed with pDBLeu-R1-parkin,
and 3 3 106 stable transformants were further transformed with 15 mg of
pPC86 human brain cDNA library (Life Tech/GIBCO). Transformants were
selected and confirmed according to the manufacturer’s instructions as previ-
ously described (Zhang et al., 2000).
Antibodies
Polyclonal PARIS antibodies were generated as described in supplemental
information. Primary antibodies used include the following: goat anti-
PGC-1a (K-15, Santa Cruz Biotechnology), mouse anti-PGC-1a (4C1.3,
Calbiochem), goat anti-NRF1 (A-19, Santa Cruz Biotechnology), rabbit
anti-NRF1 (ab34682, Abcam), mouse anti-parkin (Park8, Cell Signaling), rabbit
anti-TH (Novus Biologicals), rabbit anti-glutamate decarboxylase (GAD) 65&67
(Millipore), rabbit anti-GFP (ab661, Abcam), mouse anti-GFP (ab1218,
Abcam); Secondary antibodies used include Biotin-SP-conjugated goat
anti-rabbit (Jackson ImmunoResearch lab), donkey anti-goat-Cy3, donkey
anti-rabbit-Cy2/Cy3, donkey anti-mouse-Cy2 for immunostaining.
Plasmid Constructions
Full-length parkin, and deletion mutants, Q311X, R42P, R275W, G430D and
C431F parkin, HA-ubiquitin, PARIS, PARIS deletion and point mutations,
GST-PARIS, ZNF398 vector were constructed as described in supplemental
information. Construct integrity was verified by sequencing. Lentiviral
pLV-PGC-1a plasmid was kindly provided by Dr. Dimitri Krainc (Massachu-
setts General Hospital, Harvard Medical School, Charlestown, USA),
MYC-tagged XIAP was generously given from Dr. Kenny K. K. Chung (Hong
Kong University of Science and Technology, Clear Water Bay, Hong Kong).
Cell culture and Transfection
Human neuroblastoma SH-SY5Y cells (ATCC, Manassas, VA) were grown in
DMEM containing 10% FBS and antibiotics in a humidified 5% CO2/95% air
atmosphere at 37C. For transient transfection, cells were transfected with
indicated amounts of target vector using Lipofectamine Plus (Invitrogen),
according to manufacturer’s instructions. For coimmunoprecipitation from
cell cultures, SH-SY5Y cells were transfected with 2 mg of each plasmid,
unless otherwise indicated in supplemental information. For the ubiquitination
assay, SH-SY5Y cells were transiently transfected with 2 mg of pRK5-
Myc-tagged parkin, Myc-tagged parkin (C431F, G430D, R275W, Q311X)
pCMV-FLAG-PARIS, and 2 mg of pMT123-HA-ubiquitin plasmids for 48 hr.
For the luciferase assay SH-SY5Y cells were transiently transfected with
pCMV-empty vector or pCMV-FLAG-PARIS with either wild-type or Q311X
parkin, or pGL3-Basic, pGL3-PGC-1a promoter-Luciferase, or pGL3-PGC-
1a promoter deletion mutant (a gift from Akyoshi Fukamizu, University of
Tsukuba, Japan) (Daitoku et al., 2003) for firefly Luciferase assay and 0.1 mg
pRL-TK vector (Promega) for Renilla luciferase control.
Immunocytochemistry and Immunblot Analysis
Immunocytochemistry and immunoblot analysis was performed as described
in the supplemental information.
In vitro Interaction and Ubiquitination Assays
GST-PARIS and His-Parkin were used in in vitro interaction and ubiquitination
assays as described in the supplemental information.
CAST, EMSA, ChIP, qRT-PCR Assays
We followed a previous published protocol with modification for CAST ((Cyclic
Amplification and Selection of Targets) (Voz et al., 2000) as described in the
supplemental information. GST, GST-PARIS, GST-C571A-PARIS were used
for electrophoretic mobility shift assays (EMSA) as described in the supple-
mental information. Chromatin immunoprecipitationwas carried out according
to the manufacturer’s instruction as described in the supplemental informa-
tion. Primers used for real-time qRT-PCR are listed in Table S4.
Conditional Parkin Knockout
To generate Cre-flox conditional model of parkin knock out, a lentiviral vector
expressing GFP fused Cre recombinase (Lenti-GFPCre) was stereotaxically
introduced into exon 7 floxed parkin mice (parkinFlx/Flx) using the coordinates
in Supplemental Information. Furthermore lentiviral shRNA-PARIS was coad-
ministrated along with Lenti-GFPCre to demonstrate whether the changes in
PGC-1a and NRF-1 are due to PARIS.
Statistics
Quantitative data are presented as the mean ± SEM. Statistical significance
was either assessed via an unpaired two-tailed Student’s t test or an
ANOVA test with Student-Newman-Keuls post hoc analysis. Assessments
were considered significant with a p < 0.05.SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experiment Procedures, six
figures, and five tables and can be found with this article online at doi:10.
1016/j.cell.2011.02.010.
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